GETI.B

184.75

+0.43%↑

EKTA.B

54.45

-0.27%↓

ATT

98.6

+0.31%↑

AMBEA

127.6

+0.31%↑

ARJOB

25.28

+0.08%↑

GETI.B

184.75

+0.43%↑

EKTA.B

54.45

-0.27%↓

ATT

98.6

+0.31%↑

AMBEA

127.6

+0.31%↑

ARJOB

25.28

+0.08%↑

GETI.B

184.75

+0.43%↑

EKTA.B

54.45

-0.27%↓

ATT

98.6

+0.31%↑

AMBEA

127.6

+0.31%↑

ARJOB

25.28

+0.08%↑

GETI.B

184.75

+0.43%↑

EKTA.B

54.45

-0.27%↓

ATT

98.6

+0.31%↑

AMBEA

127.6

+0.31%↑

ARJOB

25.28

+0.08%↑

GETI.B

184.75

+0.43%↑

EKTA.B

54.45

-0.27%↓

ATT

98.6

+0.31%↑

AMBEA

127.6

+0.31%↑

ARJOB

25.28

+0.08%↑

Home・Elenco Azioni・Vivesto AB

Vivesto AB

Aperta

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

Massimo

Metriche Chiave
By Trading Economics
Entrata	-1.9M -9.1M
EPS	-0.015
Dipendenti	4
EBITDA	-1.8M -8.9M

Dividendi
By Dow Jones
Utili prossimi	7 mag 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	37M 89M
Apertura precedente	0
Chiusura precedente	0

Vivesto AB Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

25 mar 2026, 20:20 UTC

Acquisizioni, Fusioni, Takeovers

Infosys Agrees to Acquire Stratus

25 mar 2026, 23:58 UTC

Utili

Guming Proposes 2025 Final Dividend of HK$0.50 >1364.HK

25 mar 2026, 23:58 UTC

Utili

Guming: Seek to Further Expand Coffee Product Line, Explore New Food Categories >1364.HK

25 mar 2026, 23:57 UTC

Utili

Guming: Aim to Expand Store Network in China, Evaluate Overseas Opportunities >1364.HK

25 mar 2026, 23:57 UTC

Utili

Guming Store Network Rose 37% on Year to 13,554 Stores as of Dec. 31, 2025 >1364.HK

25 mar 2026, 23:56 UTC

Utili

Guming 2025 Rev CNY12.91B Vs. CNY8.79B >1364.HK

25 mar 2026, 23:56 UTC

Utili

Guming 2025 Net CNY3.11B Vs. Net CNY1.48B >1364.HK

25 mar 2026, 23:41 UTC

Discorsi di Mercato

Nikkei May Trade Rangebound Amid Uncertainty Over U.S.-Iran Talks -- Market Talk

25 mar 2026, 23:41 UTC

Utili

These Stocks Are Today's Movers: Arm, Intel, AMD, Firefly Aerospace, Robinhood, JD.com, Sarepta, and More -- Barrons.com

25 mar 2026, 23:34 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Gold Declines on Possible Technical Correction -- Market Talk

25 mar 2026, 22:08 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

25 mar 2026, 22:08 UTC

Discorsi di Mercato

Synlait Milk's Outlook Depends on Dunsandel -- Market Talk

25 mar 2026, 22:07 UTC

Utili

China Mengniu Dairy: Weak Consumer Demand Weighed on Rev >2319.HK

25 mar 2026, 22:07 UTC

Utili

China Mengniu Dairy Plans Steady Increase in Dividends For Next Three Years >2319.HK

25 mar 2026, 22:07 UTC

Utili

China Mengniu Dairy: 2025 Net Supported by Absence of Impairment Provisions Made Last Year >2319.HK

25 mar 2026, 22:07 UTC

Utili

China Mengniu Dairy 2025 Rev CNY82.24B Vs. CNY88.67B >2319.HK

25 mar 2026, 22:07 UTC

Utili

China Mengniu Dairy 2025 Net CNY1.55B Vs. Net CNY104.51M >2319.HK

25 mar 2026, 21:58 UTC

Discorsi di Mercato

Amplitude Energy Oversold on Isabella-1 Well Disappointment -- Market Talk

25 mar 2026, 21:37 UTC

Discorsi di Mercato

Miran: AI and Deregulation Are Positive Supply Shocks To Economy -- Market Talk

25 mar 2026, 21:14 UTC

Acquisizioni, Fusioni, Takeovers

St Barbara: Expects to Record Gain on Sale of Roughly A$500 Million Upon Completion

25 mar 2026, 21:13 UTC

Acquisizioni, Fusioni, Takeovers

St Barbara: All Conditions Satisfied, Waived on Lingbao Deal

25 mar 2026, 21:12 UTC

Acquisizioni, Fusioni, Takeovers

Closing M&A Deals Bring Opportunity. Janus Henderson and Other Stocks to Buy. -- Barrons.com

25 mar 2026, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

25 mar 2026, 20:50 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

Health Care Roundup: Market Talk

25 mar 2026, 20:33 UTC

Acquisizioni, Fusioni, Takeovers

KKR & Co.: Entered Agreement to Sell CoolIT Systems to Ecolab in Transaction Valued at $4.75B >KKR >KKR

25 mar 2026, 20:31 UTC

Utili

The SpaceX IPO Is Coming. Cathie Wood's Ark Venture and More Funds to Get in on the Action. -- Barrons.com

25 mar 2026, 20:15 UTC

Acquisizioni, Fusioni, Takeovers

KKR Scores One of Its Best Bets With Sale of Data-Center Cooling Business -- WSJ

25 mar 2026, 20:15 UTC

Acquisizioni, Fusioni, Takeovers

CoolIT Employees Set to Receive Average Payouts of $240,000, Executives Say -- WSJ

25 mar 2026, 20:15 UTC

Acquisizioni, Fusioni, Takeovers

CoolIT Deal Ranks Among KKR's Top-4 Highest Earning Investments in Past 20 Years, Executives Say -- WSJ

25 mar 2026, 20:15 UTC

Acquisizioni, Fusioni, Takeovers

KKR Set to Make 15x Investment From $4.75B Sale of CoolIT to Ecolab, Executives Say -- WSJ

Confronto tra pari

Modifica del prezzo

Vivesto AB Previsione

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Vivesto AB

Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer. its animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma; and Doxophos Vet, a patented formulation of doxorubicin to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was incorporated in 1988 and is headquartered in Solna, Sweden.